StockData
Inhibikase Therapeutics, Inc. logo

Inhibikase Therapeutics, Inc. (IKT) shareholders

IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38−0.07 (-4.83%)

Close on Nov 17, 2026Market cap $192.56MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
89.1%
124M of 140M shares
Institutional holders
106
19 new, 14 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $3.00M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Rajeev Shah
Joint filing with RA Capital Management, L.P. (15.90%), Peter Kolchinsky (15.90%) and 1 more
25,000,00015.90%13G (passive)Jul 10, 2026
RA Capital Healthcare Fund, L.P.
Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more
14,653,9949.90%13G (passive) amendmentJul 29, 2026
Robert Egen Atkinson
Joint filing with Commodore Capital LP (9.90%), Commodore Capital Master LP (9.90%) and 1 more
14,054,9409.90%13G (passive) amendmentMar 31, 2026
ADAR1 Capital Management, LLC
Joint filing with Daniel Schneeberger (9.90%), ADAR1 Capital Management GP, LLC (8.50%)
13,860,0289.90%13G (passive) amendmentMar 31, 2026
Sands Frank M.
Joint filing with Sands Capital Life Sciences Pulse Fund II, L.P. (9.30%), Sands Capital Alternatives, LLC (9.30%)
13,018,9659.30%13G (passive) amendmentJun 30, 2026
Joseph Edelman
Joint filing with Perceptive Advisors LLC (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%)
12,816,6439.99%13G (passive) amendmentDec 31, 2025
ADAR1 Capital Management GP, LLC
Joint filing with ADAR1 Capital Management, LLC (9.90%), Daniel Schneeberger (9.90%)
12,692,3879.90%13G (passive) amendmentDec 31, 2025
Tomas Kiselak
Joint filing with Fairmount Funds Management LLC (9.90%), Fairmount Healthcare Fund II L.P. (9.90%) and 1 more
12,461,1019.90%13G (passive) amendmentDec 31, 2025
Sands Capital Life Sciences Pulse Fund II, L.P.
Joint filing with Sands Capital Alternatives, LLC (14.70%), Sands Frank M. (14.70%)
10,950,00014.70%13G (passive) amendmentJun 30, 2025
Perceptive Advisors LLC
Joint filing with Joseph Edelman (6.90%), Perceptive Life Sciences Master Fund, Ltd. (6.90%)
10,320,8756.90%13G (passive) amendmentJun 30, 2026
Ortav Yehudai
Joint filing with Trails Edge Capital Partners, LP (6.10%), Trails Edge Biotechnology Master Fund, LP (6.10%)
8,057,3456.10%13G (passive) amendmentMar 31, 2026
BlackRock, Inc.7,768,0045.90%13G (passive)Jun 30, 2026
Soleus Private Equity Fund III, L.P.
Joint filing with Soleus Private Equity GP III, LLC (9.99%), Soleus PE GP III, LLC (9.99%) and 5 more
7,228,9089.99%13G (passive)Oct 21, 2024
Fairmount Funds Management LLC
Joint filing with Fairmount Healthcare Fund II L.P. (9.90%), Peter Harwin (9.90%) and 1 more
7,018,5759.90%13G (passive) amendmentDec 31, 2024
Trails Edge Capital Partners, LP
Joint filing with Trails Edge Biotechnology Master Fund, LP (5.10%), Ortav Yehudai (5.10%)
6,145,1985.10%13G (passive)Dec 23, 2025
SP Soleus Holdings LLC
Joint filing with Sp Ikt Holdings LLC : 83-18418459 (8.69%)
5,840,0008.69%13G (passive)Oct 21, 2024
Wilmot B. Harkey
Joint filing with Nantahala Capital Management, LLC (7.54%), Daniel Mack (7.54%)
5,298,6247.54%13G (passive)Dec 31, 2024

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of IKTValueChange% of portfolio
Sands Capital Ventures, LLC13,018,9659.33%$26.43M–4.31%
Soleus Capital Management, L.P.10,875,0007.79%$22.08M–0.76%
Trails Edge Capital Partners, LP9,051,3186.49%$18.37M+993,9732.92%
Fairmount Funds Management LLC8,625,0006.18%$17.51M–1.16%
BlackRock, Inc.7,768,0575.57%$15.77M+1,464,6240.00%
Kalehua Capital Management LLC7,643,7805.48%$15.52M+1,149,2824.95%
ADAR1 Capital Management, LLC7,387,2055.29%$15.00M+780,6330.69%
Blackstone Inc.5,938,2764.26%$12.05M–0.04%
Siren, L.L.C.5,850,0004.19%$11.88M–0.24%
Nantahala Capital Management, LLC5,403,7263.87%$10.97M+2,701,8630.18%
Commodore Capital LP5,397,4883.87%$10.96M–0.65%
Vanguard Capital Management LLC4,935,3543.54%$10.02M+484,6890.00%
Millennium Management LLC4,028,1022.89%$8.18M+1,100,0250.00%
Saturn V Capital Management LP3,869,0562.77%$7.85M+5,6111.13%
Spruce Street Capital LP3,581,6032.57%$7.27M–1.43%
Squadron Capital Management LLC3,000,0002.15%$6.09M−500,0001.89%
Geode Capital Management, LLC2,607,1291.87%$5.29M+436,9430.00%
State Street Corp1,909,1011.37%$3.88M+223,2850.00%
SummitTX Capital, L.P.1,780,2621.28%$3.61M+255,7260.09%
Integral Health Asset Management, LLC1,350,0000.97%$2.74M–0.11%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026106124M89.1%19 / 4923 / 1413M7M
Q1 2026104118M84.4%39 / 3814 / 827M11M
Q4 202574106M76.3%21 / 2715 / 152M0M
Q3 20255455M39.4%8 / 1615 / 21M1M
Q2 20254855M39.1%24 / 116 / 236M3M
Q1 20254751M36.9%19 / 123 / 32M1M
Q4 20243150M35.9%23 / 70 / 350M1M
Q3 2024111M0.6%1 / 42 / 20M0M
Q2 2024121M0.6%4 / 33 / 41M0M
Q1 2024120M0.1%3 / 34 / 20M0M
Q4 2023110M0.2%2 / 43 / 40M0M
Q3 2023130M0.3%1 / 83 / 20M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

82 funds held IKT in Q2 2026, 71% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of IKTValue% of fundAs of
Vanguard Total Stock Market Index Fund3,764,1382.70%$7.64M0.00%Jun 30, 2026
iShares Russell 2000 ETF3,009,4392.16%$6.11M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund1,320,3080.95%$2.88M0.01%Jul 31, 2026
iShares Russell 2000 Value ETF1,107,1210.79%$2.25M0.02%Jun 30, 2026
Vanguard Extended Market Index Fund1,055,7700.76%$2.14M0.00%Jun 30, 2026
Vanguard Russell 2000 Index Fund547,1920.39%$957.59K0.01%May 31, 2026
Fidelity Extended Market Index Fund421,3260.30%$737.32K0.00%May 31, 2026
iShares Micro-Cap ETF406,7110.29%$825.62K0.05%Jun 30, 2026
Schwab Small-Cap Index Fund294,0040.21%$640.93K0.01%Jul 31, 2026
Master Small Cap Index Series236,7940.17%$480.69K0.01%Jun 30, 2026
College Retirement Equities Fund - Total Global Stock Account215,7500.15%$437.97K0.00%Jun 30, 2026
JPMorgan Small Cap Value Fund171,1520.12%$347.44K0.03%Jun 30, 2026
Fidelity Small Cap Value Index Fund169,1130.12%$343.30K0.02%Jun 30, 2026
Nuveen Small Cap Blend Index Fund161,7800.12%$352.68K0.01%Jul 31, 2026
Fidelity Total Market Index Fund143,4590.10%$251.05K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Mark T. IwickiChief Executive Officer, Director––Jan 7, 2026
Milton H. WernerPresident and CEO, Director5,359,0223.84%Jan 22, 2025
Christopher CabellPresident & Head of R&D676,5640.48%Feb 24, 2026
David McIntyreChief Financial Officer10,2850.01%Jan 7, 2026
Garth Lees-RolfeChief Financial Officer––Jan 22, 2025
Scott M. WassermanDirector––Oct 21, 2026
Dennis N. BermanDirector21,8540.02%Jul 31, 2026
David CannerDirector––Jun 30, 2026
Arvind KushDirector145,0000.10%Jun 30, 2026
Vincent AurentzDirector510,5960.37%Jun 30, 2026
Amit MunshiDirector403,1760.29%Jun 30, 2026
Roberto BelliniDirector1,460,0001.05%Jun 30, 2026
Roy Lester FreemanDirector––Feb 19, 2025
Capital Healthcare Fund LP RA10% owner6,970,0005.00%Jul 31, 2026
Ra Capital Management, L.P.10% owner––Jul 31, 2026
Peter Kolchinsky10% owner––Jul 31, 2026
Rajeev M. Shah10% owner––Jul 31, 2026
Sands Capital Life Sciences Pulse Fund II, L.P.10% owner––Nov 24, 2025
Sands Capital Alternatives, LLC10% owner10,950,0007.85%Nov 24, 2025
Frank M. Sands10% owner13,018,9659.33%Nov 24, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Dennis N. Berman
Director
Jul 30, 2026Option exercise+21,854$1.26$27.54K21,854
Capital Healthcare Fund LP RA
10% owner
Jul 29, 2026Other−18,030,000––6,970,000
Vincent Aurentz
Director
Feb 21, 2026Returned to company−255,299––510,596
Christopher Cabell
President & Head of R&D
Feb 21, 2026Returned to company−338,282––676,564
Amit Munshi
Director
Feb 21, 2026Returned to company−19,089––38,176
Frank M. Sands
10% owner
Nov 21, 2025Buy+2,068,965$1.45$3.00M13,018,965
Amit Munshi
Director
Feb 21, 2025Award+57,265––57,265
Roberto Bellini
Director
Oct 21, 2024Buy+1,460,000$1.37$2.00M1,460,000
Amit Munshi
Director
Oct 21, 2024Buy+365,000$1.37$500.05K365,000
Arvind Kush
Director
Oct 21, 2024Buy+145,000$1.37$198.65K145,000
Milton H. Werner
President and CEO, Director, 10% owner
Aug 16, 2022Buy+5,000$0.80$4.00K5,335,433
Milton H. Werner
President and CEO, Director, 10% owner
May 27, 2022Buy+5,000$0.98$4.90K5,330,433
Milton H. Werner
President and CEO, Director, 10% owner
May 20, 2022Buy+10,000$0.60$6.00K5,325,433
Joseph Frattaroli
Chief Financial Officer
May 19, 2022Buy+3,948$0.64$2.53K48,091
Milton H. Werner
President and CEO, Director, 10% owner
Jan 3, 2022Option exercise+21,853$2.02$44.14K5,315,433
Milton H. Werner
President and CEO, Director, 10% owner
Nov 17, 2021Buy+1,100$1.97$2.17K23,589
Milton H. Werner
President and CEO, Director, 10% owner
Nov 17, 2021Buy+17,569$1.98$34.79K23,589
Milton H. Werner
President and CEO, Director, 10% owner
Nov 17, 2021Buy+1,334$1.94$2.59K23,589
Milton H. Werner
President and CEO, Director, 10% owner
Nov 17, 2021Buy+400$1.93$77223,589
Milton H. Werner
President and CEO, Director, 10% owner
Nov 17, 2021Buy+3,186$1.96$6.24K23,589
Milton H. Werner
President and CEO, Director, 10% owner
Aug 17, 2021Option exercise+21,853$2.02$44.14K5,293,580
Milton H. Werner
President and CEO, Director, 10% owner
May 14, 2021Tax withholding−16,918$4.59$77.65K5,271,727
Milton H. Werner
President and CEO, Director, 10% owner
May 14, 2021Option exercise+43,707$0.38$16.61K5,288,645
Joseph Frattaroli
Chief Financial Officer
Dec 28, 2020Conversion+44,143$10.00$441.43K44,143

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
16.47%
19M shares short
Days to cover
28.6
At 1M shares a day
Change since last report
-1.0%
From 20M shares
Short volume, 20 days
60.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Inhibikase Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 6,166 shares on Sep 10, 2026 over the last 90 days.

See a number that looks wrong?